The impact of albumin infusion on the risk of rebleeding and in-hospital mortality in cirrhotic patients admitted for acute gastrointestinal bleeding: a retrospective study of a single institute.
Albumin
Cirrhosis
Gastrointestinal bleeding
Portal hypertension
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
23 Jun 2020
23 Jun 2020
Historique:
received:
24
12
2019
accepted:
08
06
2020
entrez:
25
6
2020
pubmed:
25
6
2020
medline:
15
5
2021
Statut:
epublish
Résumé
To investigate the effect of albumin infusion on cirrhotic patients admitted for acute gastrointestinal bleeding. Medical records of cirrhotic patients who admitted due to acute gastrointestinal bleeding through January 2009 to December 2018 were reviewed. Clinical data and the total amount of albumin and red blood cell used during hospitalization were recorded. For patients with rebleeding, the amount of albumin and red blood cell used before rebleeding was also documented. The primary outcome was the occurrence of rebleeding, and the second outcome was in-hospital mortality. Univariate and multivariate logistic analysis was performed to identify risk factors associated with rebleeding and in-hospital mortality. A total of 1503 cirrhotic patients were included in the analysis. There were 146 episodes of in-patient rebleeding occurred, while 81 patients died. Overall, more red blood cells and albumin were prescribed to patients who suffered rebleeding. In terms of the amount before rebleeding, the red blood cell was higher in patients with rebleeding, but the albumin infusion was similar. In the multivariate model, the albumin infusion before rebleeding was an independent risk factor associated with rebleeding (adjusted OR for ≤40 g vs 0 g, 0.469 [0.269-0.793], p = 0.006; adjusted OR for > 40 g vs 0 g, 0.272 [0.115-0.576], p = 0.001). In Child-Pugh C class patients, the use of albumin more than 40 g during hospitalization associated with a lower risk of in-patient mortality (adjusted OR for > 40 g vs 0 g, 0.136 [0.019-0.741], p = 0.031). Albumin infusion was associated with a lower risk of rebleeding and in-hospital deaths in cirrhosis admitted for acute gastrointestinal bleeding.
Sections du résumé
BACKGROUND
BACKGROUND
To investigate the effect of albumin infusion on cirrhotic patients admitted for acute gastrointestinal bleeding.
METHODS
METHODS
Medical records of cirrhotic patients who admitted due to acute gastrointestinal bleeding through January 2009 to December 2018 were reviewed. Clinical data and the total amount of albumin and red blood cell used during hospitalization were recorded. For patients with rebleeding, the amount of albumin and red blood cell used before rebleeding was also documented. The primary outcome was the occurrence of rebleeding, and the second outcome was in-hospital mortality. Univariate and multivariate logistic analysis was performed to identify risk factors associated with rebleeding and in-hospital mortality.
RESULTS
RESULTS
A total of 1503 cirrhotic patients were included in the analysis. There were 146 episodes of in-patient rebleeding occurred, while 81 patients died. Overall, more red blood cells and albumin were prescribed to patients who suffered rebleeding. In terms of the amount before rebleeding, the red blood cell was higher in patients with rebleeding, but the albumin infusion was similar. In the multivariate model, the albumin infusion before rebleeding was an independent risk factor associated with rebleeding (adjusted OR for ≤40 g vs 0 g, 0.469 [0.269-0.793], p = 0.006; adjusted OR for > 40 g vs 0 g, 0.272 [0.115-0.576], p = 0.001). In Child-Pugh C class patients, the use of albumin more than 40 g during hospitalization associated with a lower risk of in-patient mortality (adjusted OR for > 40 g vs 0 g, 0.136 [0.019-0.741], p = 0.031).
CONCLUSIONS
CONCLUSIONS
Albumin infusion was associated with a lower risk of rebleeding and in-hospital deaths in cirrhosis admitted for acute gastrointestinal bleeding.
Identifiants
pubmed: 32576140
doi: 10.1186/s12876-020-01337-5
pii: 10.1186/s12876-020-01337-5
pmc: PMC7310478
doi:
Substances chimiques
Albumins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
198Subventions
Organisme : Department of Science and Technology of Sichuan Province
ID : 2017FZ0091
Références
Gastroenterology. 2019 Jul;157(1):149-162
pubmed: 30905652
Lancet Gastroenterol Hepatol. 2017 May;2(5):354-360
pubmed: 28397699
J Hepatol. 2012 Oct;57(4):759-65
pubmed: 22732511
Hepatology. 2013 Nov;58(5):1836-46
pubmed: 23423799
Dig Dis Sci. 2013 Nov;58(11):3232-41
pubmed: 23934414
Hepatology. 2004 Mar;39(3):746-53
pubmed: 14999693
Gut. 2015 Nov;64(11):1680-704
pubmed: 25887380
Clin Gastroenterol Hepatol. 2013 Feb;11(2):123-30.e1
pubmed: 23178229
J Crit Care. 2016 Jun;33:62-70
pubmed: 26831575
N Engl J Med. 2013 Jan 3;368(1):11-21
pubmed: 23281973
Crit Care. 2015 May 05;19:202
pubmed: 25939346
Gut. 2018 Oct;67(10):1757-1768
pubmed: 29691276
J Hepatol. 2015 Apr;62(4):822-30
pubmed: 25463545
J Hepatol. 2010 Oct;53(4):762-8
pubmed: 20638742
Hepatology. 2003 Sep;38(3):599-612
pubmed: 12939586
Semin Respir Crit Care Med. 2012 Feb;33(1):46-54
pubmed: 22447260
Lancet. 2015 Jul 11;386(9989):137-44
pubmed: 25956718
Surg Today. 2016 Oct;46(10):1138-45
pubmed: 26818192
Dig Dis Sci. 2019 Jun;64(6):1419-1431
pubmed: 30684079
Crit Care. 2014 Dec 15;18(6):702
pubmed: 25499187
Liver Int. 2017 Jan;37 Suppl 1:104-115
pubmed: 28052623
Clin Gastroenterol Hepatol. 2018 May;16(5):748-755.e6
pubmed: 28911947
Chin Med J (Engl). 2009 Apr 5;122(7):766-75
pubmed: 19493387
Clin Transl Gastroenterol. 2018 Mar 29;9(3):138
pubmed: 29599508